Biomea Fusion, Inc. ("Biomea" or the "Company") (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing ...

Biomea Fusion has escaped from the full clinical hold imposed by the FDA. After reviewing the data, the regulator has cleared Biomea to study its diabetes drug candidate under a revised protocol ...

Biomea Fusion Inc. (BMEA) announced that the U.S. Food and Drug Administration has lifted the clinical hold on the company's ongoing ...

Fintel reports that on September 26, 2024, Rodman & Renshaw upgraded their outlook for Biomea Fusion (NasdaqGS:BMEA) from ...

Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any ...

This summary highlights major health news, including Bavarian Nordic's UNICEF agreement for mpox vaccines, Pfizer's ...

Analyst Srikripa Devarakonda of Truist Financial maintained a Hold rating on Biomea Fusion (BMEA – Research Report), with a price target ...

Biomea Fusion said the Food and Drug Administration lifted its clinical hold on continuing clinical trials of the company's diabetes drug.

The drug, BMF-219, is being tested in an early-to-mid stage study for type 2 diabetes and a mid-stage study for type 1 ...

Biomea Fusion said on Thursday the U.S. Food and Drug Administration lifted a clinical hold on ongoing studies of its ...